RVNC Revance Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RVNC

Price (delayed)

$3.95

Market cap

$348.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.83

Enterprise value

$689M

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide ...

Highlights
Revance Therapeutics's gross profit has soared by 97% YoY and by 19% from the previous quarter
RVNC's revenue has soared by 77% YoY and by 9% from the previous quarter
Revance Therapeutics's equity has decreased by 43% from the previous quarter
Revance Therapeutics's quick ratio has decreased by 32% YoY and by 20% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.revance.com
Peers: JNJ MNOV BIIB

Key stats

What are the main financial stats of RVNC
Market
Shares outstanding
88.21M
Market cap
$348.45M
Enterprise value
$689M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.94
Earnings
Revenue
$234.04M
EBIT
-$304.33M
EBITDA
-$290.64M
Free cash flow
-$223.46M
Per share
EPS
-$3.83
Free cash flow per share
-$2.64
Book value per share
-$1.73
Revenue per share
$2.77
TBVPS
$5.54
Balance sheet
Total assets
$478.45M
Total liabilities
$630.06M
Debt
$478.43M
Equity
-$151.6M
Working capital
$249.64M
Liquidity
Debt to equity
-3.16
Current ratio
3.8
Quick ratio
3.16
Net debt/EBITDA
-1.17
Margins
EBITDA margin
-124.2%
Gross margin
68.2%
Net margin
-138.4%
Operating margin
-135.4%
Efficiency
Return on assets
-60.1%
Return on equity
N/A
Return on invested capital
-42.9%
Return on capital employed
-78.2%
Return on sales
-130%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVNC stock price

How has the Revance Therapeutics stock price performed over time
Intraday
4.77%
1 week
16.18%
1 month
-13.19%
1 year
-88.25%
YTD
-55.06%
QTD
-19.72%

Financial performance

How have Revance Therapeutics's revenue and profit performed over time
Revenue
$234.04M
Gross profit
$159.68M
Operating income
-$316.78M
Net income
-$323.99M
Gross margin
68.2%
Net margin
-138.4%
Revance Therapeutics's gross profit has soared by 97% YoY and by 19% from the previous quarter
RVNC's revenue has soared by 77% YoY and by 9% from the previous quarter
Revance Therapeutics's net margin has increased by 49% YoY and by 28% QoQ
The operating margin is up by 48% year-on-year and by 29% since the previous quarter

Growth

What is Revance Therapeutics's growth rate over time

Valuation

What is Revance Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.94
The EPS rose by 24% QoQ and by 22% YoY
Revance Therapeutics's equity has decreased by 43% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 532.0 and 85% lower than the last 4 quarters average of 9.0
RVNC's revenue has soared by 77% YoY and by 9% from the previous quarter

Efficiency

How efficient is Revance Therapeutics business performance
The ROS rose by 49% YoY and by 30% QoQ
The ROIC has grown by 24% from the previous quarter and by 12% YoY
The ROA has increased by 18% QoQ but it has decreased by 5% YoY

Dividends

What is RVNC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVNC.

Financial health

How did Revance Therapeutics financials performed over time
The total assets is 24% less than the total liabilities
Revance Therapeutics's quick ratio has decreased by 32% YoY and by 20% from the previous quarter
The current ratio has contracted by 23% YoY and by 20% from the previous quarter
The debt to equity has dropped by 110% year-on-year but it is up by 31% since the previous quarter
Revance Therapeutics's equity has decreased by 43% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.